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Introduction: The World Health Organization identified Pharmaceutical and Therapeutics
Committees (PTCs) at district and hospital levels as one of the pivotal models to promote
rational use of medicines (RUM). This is endorsed by the Government in South Africa.
Formulary development and management is one of the main functions of PTCs. This study
aimed to describe the formulary management activities among PTCs in public hospitals in
Gauteng Province, South Africa, following initiatives to promote RUM in South Africa.
Methods:Qualitative, nonparticipatory, observational study, observing 26 PTCmeetings.
Data were coded and categorized using NVivo9® qualitative data analysis software.
Themes and sub-themes were developed. The themes and sub-themes on formulary
management are the principal focus of this paper.
Results: More than half of the observed PTCs reviewed their formulary lists. There was
variation in the review process among institutions providing different levels of care. Various
aspects were considered for formulary management especially requests for medicines to
be added. These included cost considerations (mainly focusing on acquisition costs),
evidence-based evaluation of clinical trials, patient safety, clinical experience and changes
in the National Essential Medicines List (NEML). The tertiary PTCs mostly dealt with
applications for new non-EML medicines, while PTCs in the other hospitals mainly
requested removal or addition of EML medicines to the list.
Conclusion: This is the first study from Gauteng Province, South Africa, reporting on how
decisions are actually taken to include or exclude medicines onto formularies within public
sector hospitals providing different levels of care. Various approaches are adopted
at different levels of care when adding to- or removing medicines from the formulary
lists. Future programs should strengthen PTCs in specialized aspects of formulary
management. A more structured approach to formulary review at the local PTC levelin.org August 2020 | Volume 11 | Article 12671
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additions to the NEML.Keywords: formulary, management, essential medicines, rational medicine use, list (data structure),
pharmaceutical and therapeutics committees, South AfricaBACKGROUND
Access to and affordability of medicines is a challenge especially
in low- and middle-income countries (LIMCs) including
South Africa (Cameron et al., 2009; Leisinger et al., 2012;
Attaei et al., 2017; Wirtz and Moucheraud, 2017; Chigome
et al., 2019). One way to address this is to improve the
appropriate use of medicines, given that more than half of all
medicines are prescribed or dispensed inappropriately with
approximately half of all patients failing to take their
medicines correctly (World Health Organization, 2012; Ofori-
Asenso and Agyeman, 2016). Appropriate use of medicines also
reduces the extent of adverse drug reactions with their impact on
morbidity, mortality and costs (Davies et al., 2009; Chiatti et al.,
2012; Gyllensten et al., 2013; Formica et al., 2018). One
recognized way to improve medicine use across LMICs is to
ensure access to, and availability of, a core list of well proven and
cost-effective medicines alongside measures to enhance universal
healthcare, which was the concept behind the WHO’s Essential
Medicines List (EML) (WHO Policy Perspectives on Medicines,
2002; World Health Organisation, 2015; Wirtz et al., 2017;
Holloway et al., 2020).
The WHO’s recommendations for essential medicines
programs encourage the use of formularies, as essential tools for
the appropriate, safe and cost-effective use of medicines in order
to promote the rational use of medicines (RUM) (Gustafsson
et al., 2011; Schiff et al., 2012; Quick et al., September 2002).
Formularies are seen as important for delineating and directing
appropriate prescribing enhanced by trust in their development
(Rucker and Schiff, 1990; Pillans et al., 1992; Eriksen et al., 2018).
This is especially important when the principal means of
physician education is via pharmaceutical companies (Spurling
et al., 2010; Civaner, 2012; Jacob, 2018; Fadare et al., 2018a;
Fadlallah et al., 2018).
The WHO identified Pharmaceutical and Therapeutics
Committees (PTCs), also referred to as Drugs and Therapeutics
Committees (DTCs) in a number of countries (Bjorkhem-Bergman
et al., 2013; Hoffmann, 2013), at district and hospital levels as one of
the pivotal models to promote RUM (Holloway and Green, 2003;
Office of Director of Pharmaceutical Services (ODPS) Ministry of
Health Ghana, 2015). Furthermore, a limited list of medicines for
procurement, based on an EML or formulary, helps define which
medicines should be regularly purchased and prescribed.
Consequently, PTCs are seen as one of the most effective ways to
control medicine usage and expenditure (Norman et al., 2009;
Bjorkhem-Bergman et al., 2013; Tseng et al., 2016; Shirneshan
et al., 2016; Meyer et al., 2017; Leporowski et al., 2018).
Formulary development and management is one of the key
functions of PTCs (Holloway and Green, 2003; Hoffmann, 2013;in.org 2Plet et al., 2013; Lima-Dellamora Eda et al., 2014; Matlala et al.,
2017). A PTC can also provide the leadership and structure
needed to select appropriate medicines for inclusion in the
formulary, promote RUM, educate physicians on evidence-
based medicine (EBM) and reduce waste, thereby optimizing
medicine expenditure and improving patient outcomes within
available resources (Wu and Miao, 2008; Bjorkhem-Bergman
et al., 2013; Hoffmann, 2013; Lima-Dellamora Eda et al., 2014).
Decisions for the listing of medicines on formularies, including
new medicines, should be based on clinical, ethical, legal, social,
philosophical, quality-of-life, safety and economic factors
(Holloway and Green, 2003; Jenkings and Barber, 2004; Tyler
et al., 2008; Puigventos et al., 2010; Gustafsson et al., 2011;
Hoffmann, 2013; Plet et al., 2013). Decisions should also take
into account issues such as access and implementation as well as
follow-up and procurement (Pharasi and Miot, 2013; Lima-
Dellamora Eda et al., 2014; Meyer et al., 2017; Matlala et al.,
2017). In addition, local knowledge should be taken into
consideration, although decisions should be based on scientific
rationality (Jenkings and Barber, 2004; Bjorkhem-Bergman
et al., 2013).
There has been considerable development toward universal
healthcare in South Africa in recent years in preparation for the
implementation of National Health Insurance (NHI) to address
previous inequalities for the majority of patients in South Africa
(Meyer et al., 2017).Within this system, public hospitals are funded
on an activity basis which includes the costs of medicines.
Consequently, recommendations for prescribed medicines need
to follow a rigorous and encompassing process to optimize the use
of available resources (Meyer et al., 2017). The use of EBM as a key
criteria for the selection of medicines for their inclusion into the
Standard Treatment Guidelines and Essential Medicines List
(STGs/EML) in South Africa has become robust and stringent
with time (Republic of South Africa, 2018; National Department of
Health, 2019). The basic criteria for medicines selection in South
Africa is stipulated in the National Drug Policy, with the EML as
the foundation for the development of STGs aimed at improving
patient care (South African National Department of Health, 1996).
The STGs/EML are regularly updated and available electronically
to enhance their use (Meyer et al., 2017).
The selection of medicines that are available in the public
healthcare sector currently takes place through the National
Essential Medicines List Committee (NEMLC) as well as
provincial and facility based PTCs (Meyer et al., 2017; Republic
of South Africa, 2018). Two essential tasks of PTCs within the
public healthcare system are to develop and revise institutional
STGs (usually adapted from national guidelines) and to maintain
an institutional formulary, based on the national EML (Laing
et al., 2001; Holloway and Green, 2003; Fadare et al., 2018b). TheAugust 2020 | Volume 11 | Article 1267
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according to the level of care, as outlined in the National PTC
guidelines (South African National Department of Health, 2019).
The Master Health Product List, which contains both EML and
non-EML medicines, is the main document used to derive the
respective institutional or level of care formulary lists as
demonstrated in Figure 1. Tertiary level PTCs can evaluate
potential non-EML medicines for inclusion in the hospital
formulary; with secondary care and other hospitals confined to
the EML in their deliberations.
In addition, PTCs monitor drug utilization against agreed
guidance (Bjorkhem-Bergman et al., 2013; Eriksen et al., 2017;
Leporowski et al., 2018). The PTCs within hospitals or
from primary healthcare (PHC) facilities through their district
PTCs, which are considered as Expert Review Committees,
subsequently make recommendations for new medicines to be
included in the STGs/EML (Matlala et al., 2017; Meyer et al.,
2017; Mashaba et al., 2019).
The National Policy for the Establishment and Functioning of
PTCs in South Africa outlined the standards for PTCs at all levels
in South in 2015 (NDOH, 2015). The Policy also stipulates that
PTCs should exist at provincial, district, sub-district (where
applicable) and health establishment (Regional, Tertiary,
Central and District Hospital) with, as mentioned, different
degrees of freedom depending on their level of specialization.
Consequently, the number of PTCs in each Province depends on
the number of hospitals and districts. The composition and
functions of PTCs in public sector hospitals within the
Gauteng Province have been discussed in previously published
studies (Matlala et al., 2017; Mashaba et al., 2019), including the
number of meetings per annum, the activities carried out by
these PTCs, the types of subcommittees within the PTC and their
degree of freedom (NDOH, 2015; Matlala et al., 2017). The
National and the Gauteng Provincial guidelines for PTCs in
South Africa stipulate that PTCs should develop a formularyFrontiers in Pharmacology | www.frontiersin.org 3aligned to agreed treatment guidelines and protocols, and
subjected to robust evidence-based interrogation (Gauteng
Province Department of Health, 2013; NDOH, 2015). This
process of evaluation must be conducted using explicit
documented criteria, allowing for transparent evaluation of the
decision and facilitating any reviews. This includes information
on the pharmacological action of the medicine as well as its
health gain versus current medicines on the formulary and the
strength of the evidence (Gauteng Province Department of
Health, 2013), with applications made on official forms.
Even though PTCs have been active in South Africa since the
mid 1990s, little is known about the actual formulary
management within South African public sector hospitals
(Matlala et al., 2017; Perumal-Pillay and Suleman, 2017). This
study aims to describe formulary management practices in public
sector hospitals in the Gauteng Province of South Africa, and to
recommend strategies to improve formulary management by
PTCs in this province and wider, should this be necessary. This
builds on our recent publications describing ongoing processes
in the public health system in South Africa to improve the quality
and efficiency of medicine use (Meyer et al., 2017), as well as the
structure and functioning of PTCs among public sector hospitals
(Matlala et al., 2017; Mashaba et al., 2019).METHODS
A qualitative, nonparticipatory, observational method was
employed for this study. Data collection entailed the
observation of a total number of 26 PTC meetings (amounting
to at least two meetings per PTC), conducted by 13 PTCs in the
Gauteng Province, over a period of 12 months from February
2013 to February 2014. Requests to attend each of the scheduled
PTC meetings were sent to all the responsible pharmacists at the
hospital level, the district pharmacist and the chairperson of theFIGURE 1 | Hierarchy of Formulary Development and Management in the Public Sector – adapted from (South African National Department of Health, 2019).August 2020 | Volume 11 | Article 1267
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objectives of the study, proof of ethical clearance and evidence
of provincial approval were included in the communication.
In the instances where the chairperson of the PTC did not
allow recording of the proceedings, notes of the discussions were
taken and subsequently verified against the minutes of the
meeting from the secretariat of the particular PTC. However,
this was the case for only the Provincial PTC meetings.
Observations were undertaken as discreetly as possible so as to
not influence the proceedings of the PTC meetings. The
observations were conducted until data saturation was reached.
The recorded data were transferred from the digital voice
recorder to a computer and stored as Windows Media Audio
files. The recording of each observed PTC meeting was
transcribed verbatim, typed in Microsoft Word® and stored as
a separate document. The transcribed observations were then
verified against the audio recordings for accuracy, after which
they were imported into NVivo® (Version 9) a software program
for qualitative data analysis. Typed-up observational notes of
PTC meetings which were not audio recorded, were also
imported into NVivo®.
Two of the authors (MM and JCM) performed a thematic
analysis of the data using open coding (Table 1) (Braun and
Clarke, 2006). The transcripts and observational notes were first
read and re-read to explore and obtain an understanding of the
data. A list of possible codes was compiled from the initial
reading of the data, which were used as the starting point for
coding with the software. Through consensus discussions
between the two coders, code-recoding procedures were
employed to increase the consistency (dependability) of the
findings. Connections between codes were identified and
categories created. Additional codes and categories were
created as new topics emerged. The categories were reviewed
and discussed with the other co-authors for consensus of coding
and emergent themes and subthemes. The themes and
subthemes specifically relating to formulary management were
identified as the focus point for this paper.
The results are presented according to the themes and sub-
themes that emerged from the data with verbatim quotations
of discussions from PTC members inserted to support the
findings. A coding system was used to protect the identity ofFrontiers in Pharmacology | www.frontiersin.org 4the participating PTCs and its members. Quotations were
credited to specific PTCs and participants by using a dedicated
reference code for the observation of a particular PTC according
to the level of care and the meeting observed. Quotations are
presented in italics and enclosed in inverted commas. Identifiers
of the participants are provided in square brackets after each
quotation to enhance understanding. Explanations included in
the quotations are presented as normal text and enclosed in
round brackets. Table 2 provides details of the codes assigned to
PTC observations.
Ethics Statement
The Medunsa Research Ethics Committee of the University
of Limpopo (Medunsa Campus), now Sefako Makgatho
Health Sciences University, granted ethical clearance for the
study (MREC/H/170/2010:PG). Approval from the Gauteng
Provincial Department of Health Research Committee was
obtained prior to the study implementation. Chairpersons of
the respective PTCs provided permission to record or take notes
of proceedings.RESULTS
Thematic Analysis of Content
The thematic analysis of the content of the observational
transcripts resulted in seven major themes and subthemes,
which are summarized in Table 3.
Theme 1: Application of EBM Principles
When an application for new medicines outside of the current
hospital formulary list, and in some cases outside the EML, were
presented at the PTC, either the chairperson or the secretariat
first introduced the request. The clinician who submitted the
request, if present at the meeting, was subsequently asked to
present the rationale behind the request. In the presentations at
tertiary and regional PTCs, the clinicians typically provided a
summary of a clinical trial that demonstrated the benefits of the
medicine being requested for inclusion. This was typically not
the case in secondary and primary care hospitals.TABLE 2 | Reference codes assigned to Pharmaceutical and Therapeutics













Notes taken from observation of PTC meeting at
a tertiary Hospital
[Ob Th
PTC]August 2020 | Volume 11 |TABLE 1 | Data analysis process.
Steps of analysis Tasks completed
Step 1: Data
familiarization
Transcription, verification of transcripts against audio
recordings and field notes, as well as re-reading of
transcripts
Step 2: Initial codes
development
Initial open coding of the entire data set
Step 3: Identification of
theme
Categorization of codes into potential themes
Step 4: Review of themes Confirming themes - ensuring the internal
homogeneity and external heterogeneity of themes
Step 5: Defining and
naming of themes
Further refinement of themes, specifically identifying
those that relate to formulary management
Step 6: Report finalization Production of the manuscript, selection of illustrative
quotesArticle 1267
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The common features of the evidence presented were the
comparison of a new medicine to an existing medicine in a
Cochrane review (e.g. balanced salt solution). Survival rates were
also referred to in some instances (e.g. for a proposed oncology
medicine). In the case of a proposed oncology medicine, several
clinical trials were presented to indicate an improvement in
survival. In other instances, clinical trial information was used to
demonstrate improved morbidity.Fronti“Diffuse large B cell lymphomas are potentially curable
and pre-treatment variables do predict for prognosis
and response to treatment. With an IPI score of zero
there is about a 94% survival at 4 years, if the patients
are treated with a standard chemotherapy including
rituximab, and a lower IPI score then there is about
50% survival at five years”. [Ob Th PTC]It was evident that the principles of EBM were used in
decision-making at tertiary hospital PTCs. The clinician also
discussed the outcomes of treatment when an alternative
management approach was compared to the use of the
medicine being considered. This is illustrated by an example
where the results of using radiation alone, instead of using the
anticancer medicine, was highlighted.“Results in the treatment of diffuse large B cell
lymphomas, if untreated survival can be measured in
months. Radiation therapy has been looked at in diffuse
large B cell lymphomas, but recurrence occurs at a rate
of 70%, so radiation therapy is not first line treatmenters in Pharmacology | www.frontiersin.org 5or the second line treatment and only in certain cases is
it indicated as consolidation therapy”. [Ob Th PTC]The discussion was further informed by highlighting the
overall survival rate when using the medicine being requested.“They were able to demonstrate that rituximab together
with CHOP resulted in significant improvement in
overall survival at 7 years and event free survival of
about 32% and a 10 years overall survival of 44%”. [Ob
Th PTC]Subtheme 1b: Patient Safety
The PTCs in secondary and other hospitals also considered EBM
principles in submissions, though to a lesser extent. The main
considerations for including new medicines into hospital
formularies were relative risk reduction, clinical benefits and
patient safety.
The relative risk or side effect profiles of the new medicine
were mentioned with reference to international commentary, as
illustrated below.“There was no difference between efficacy and side
effects when used in children. Although in this
European comment they say that zelondronic
acid may result in some minor complications like
the inflammatory type of reaction, unexplained
tachycardia, acute phase response and decreased
calcium levels, are more prominent with the use of
zelondronic acid. The side effects are often relative”.
[Ob Th PTC]In some instances, patient safety was also a motivation when
medicines were removed from the formulary.“Phenytoin IV is not safe to use at the primary care
level because of the required monitoring, other
anticonvulsants can be used to control patients that
present at the primary clinic with a fit and the patient
can then be transferred to the hospital once controlled.
Oral anticonvulsants can be given to patients that can
swallow which are much safer than the IVI; the IVI can
be given at the hospitals where monitoring takes place”.
[Ob D PTC]In all cases, presentations were followed by questions from
committee members and subsequent discussion, before a
decision was taken to accept or reject the request.
Theme 2: Cost Considerations
Cost was one of the main considerations when new medicines
were requested for addition to the formulary at all levels of care.
The cost was typically referred to as the cost per dose, cost per
patient, or an estimate of the total annual drug expenditure. At
the time of this study, there was little consideration of formal
health economic argumentation such as cost per quality adjusted
life year.TABLE 3 | Summary of themes and subthemes relating to formulary management.
Category Themes and subthemes




• Cost minimization analysis
• Estimated annual expenditure
Resources Expertise and experience
• Pharmacoeconomic Expertise
• Clinical Experience
Controls Internal and external controls
• EML/STG reviews
• Provincial guidelines
Outputs Acceptance of application
• Cost savings
• Restricted patient use
• Conditional up-referral of decision to management
• Development of clinical guidelines for accepted medicine
Decline of application
• Requested medicine not registered for indication
• Insufficient evidence from data presented




• Level of care
• Cost of medicinesAugust 2020 | Volume 11 | Article 1267
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There was a difference in the cost considerations with regard to
the hospital level. Most new medicine considerations at tertiary
level hospital PTCs were mainly for non-EMLmedicines. In such
instances, the acquisition costs of the new medicines were
compared to similar agents in the hospital. In some cases,
additional costs, such as mode of administration and costs of
other monitoring measures were also considered.Fronti“The cost of Actilyse® is about R3 000.00 or R4 000.00
per vial, which is marginally less expensive than the cost
of Metalyse®, but Metalyse® is more effective as there
are no infusion pumps and drips sets, so it ends up
working out to be much cheaper”. [Ob Th PTC]Subtheme 2b: Estimated Annual Expenditure
Estimated annual expenditure was often referred to when the
proposed newmedicine was going to be used in only a few patients.“It is terribly expensive, and this is a lifelong treatment,
this was discussed with the finance officer. Often
acromegaly patients can be treated with up to 1mg
per day; the LAR is 20mg monthly, which works out to
R21 000.00 per month. The yearly cost is more than
R210 000.00”. [ObTh PTC]Similarly, the cost per patient was often used in discussions,
especially when the acquisition cost of the proposed medicine
was high.“In severe over reactive bladder they need botox intravisicle
once off and it is then repeated once a year. It is a very
important problem. The cost will be R1 950.00 per patient
that adds up to R4 000.00 per year for the two patients. It
might be repeated after one year”. [Ob Th PTC]Theme 3: Expertise and Experience
Subtheme 3a: Pharmacoeconomic Expertise
There was a perceived lack of expertise in pharmacoeconomic
evaluations among PTC members. In one of the observations, a
member of the tertiary level PTC highlighted the fact that they
lacked expertise in undertaking or fully assessing a formal economic
evaluation when considering whether to list newmedicines onto the
formulary. This is an area to address in the future.“One of the things that are needed in the hospital is a
health economist, because the committee is looking at
just the drug costs as opposed to looking at all the other
costs. If a cost-minimisation analysis was done, one
might find that it is cheaper to give the medicine than
treating the heart failure with all the other things the
patients get”. [Ob Th PTC]Subtheme 3b: Clinical Experience
When a new medicine was being proposed especially for a non-
EML medicine, the indication of the medicine was outlined anders in Pharmacology | www.frontiersin.org 6the clinician sometimes highlighted his/her clinical experience
with the use of the particular medicine, e.g. a new treatment of
type B cell lymphoma:“Diffuse large B cell lymphomas are potentially curable
and pre-treatment variables do predict good prognosis
and response to treatment. With an IPI score of zero
there is about a 94% survival at 4 years, if the patients
are treated with a standard chemotherapy, including
rituximab and a lower IPI score then there is about 50%
survival at five years”. [Ob Th PTC]In some instances, clinicians did not make specific reference
to clinical trials. In these situations, they alluded to evidence that
had demonstrated clinical benefit to the patient. The following
observation illustrates how in this case the clinician used the
experience from a tertiary hospital as a point of reference for
the request:“This has become the procedural sedation of choice in
high risk patient population groups, which is why in
ICU use it gives a very different quality of sedation.
Patients are clear, they are not as sedated as they are
with benzodiazepines, where there is often difficulty
with differentiating between delirium and nondelirium
state. There is often synergism between benzodiazepines
and other agents at the Gama Amino Butyric Acid
receptor site that leads to marked haemodynamic
instability intra-operatively. These medicines are now
currently being used worldwide to perform these types
of procedures specifically in high risk patient population
groups”. [Ob Rh PTC]Theme 4: Internal and External Controls
Subtheme 4a: EML/STG Reviews
At district hospitals, discussions typically focused on formulary
reviews. The pharmacists in the PTCs typically presented most of
these discussions and submissions. The reviews were based on
EMLmedicines, which needed to be included or removed from the
formulary list. Some of the discussions were based on clinicians
requesting medicines which were already on the EML but not
available in their respective institutions. In these instances, the cost
of the requested medicine was typically compared to a similar
agent that was already being used in the hospital to justify
inclusion, as illustrated by the following example:“The pharmacy received a request for captopril, as it is
on the EML. However, the price of a packet of 56
captopril 25mg tablets is R6.79 and the price of 28
enalapril tablets is R2.60, and packet of 28 tablets
perindopril costs R14.91”. [Ob Dh PTC]In some cases, the use of a different formulation was
encouraged, also based on cost, as demonstrated with the use
of risperidone tablets:August 2020 | Volume 11 | Article 1267
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Fronti“Risperdal® (Risperidone) 1mg tablets versus the syrup -
the pharmacy requested that patients where possible be
prescribed the tablets instead of the syrup, because the
tablets’ tender price is R8.95 per packet whereas the
syrup costs R181.00 per bottle”. [Ob Dh PTC]Subtheme 4b: Provincial Guidelines
The fact that formulary reviews at district hospitals was
determined by the provincial formulary can be confirmed by
one of the observations from the provincial PTC:“There are items that need to be removed from the local
formulary in order to be in line with the provincial
formulary”. [Ob P PTC]Provincial treatment guideline updates influenced decisions
for removal of medicines in district/ secondary hospital PTCs, as
illustrated below.“It was decided to remove the following medicines:
griseofulvin tablets because it is not in the guidelines”.
[Ob D PTC]Formulary decision-making for new proposed medicines as
observed in this study were either accepted or declined. The
decisions were made in consultation with the entire committee
following rigorous discussions among the PTC members.
Theme 5: Acceptance of Application
Subtheme 5a: Cost Savings
Perceived cost savings that could be achieved was one of the
motivating factors in PTCs accepting a request for a new medicine
to be included in the hospital formulary. An observed example
was for an ophthalmic preparation, where the proposed medicine
was identified as cheaper than the alternative currently being used
at the hospital, even though it was equally efficacious. The
committee accepted the request based on lower acquisition costs.“The other motivation from ophthalmology is for
Alphagan® (bromonidine) it is indicated for glaucoma,
specifically for patients not responding to available
treatment. The patients would be on one of the drugs
available, if one wants to defer surgery an alpha-2
agonist can then be used. The cost for Betagan®
(levobunolol) in this class is the lowest. The patients
seen can be about 20 a year, but there is also the option of
surgery. If the patient is on Trusopt® (dorzolamide) and
Alphagan® is added on then it becomes expensive, but if
the prescriber were to stop the Trusopt® and then add
the Alphagan® it would not make a difference because
they cost the same. It is approved for 20 patients per year;
it will be useful to give feedback to the PTC regarding
patient progress”. [Ob Th PTC]Subtheme 5b: Restricted Patient Use
Proposals were sometimes accepted for restricted patient use, but
only where the patient population was clearly defined.ers in Pharmacology | www.frontiersin.org 7“It would have to be stipulated that these agents will be
reserved for high risk patient groups in theatre and for
patients from cardiology coming for vascular procedures
which are done noninvasively”. [Ob Th PTC]Subtheme 5c: Conditional Up-Referral of a Decision to
Management
Some of the proposed new medicines were referred to the
hospital administrators to decide whether to purchase or not,
especially medicines which are perceived to be too expensive,
following PTC support, based on clinical reasons. The PTC
agreed that the medical indication exists, it was then up to the
hospital’s management (referred to as the office of the Chief
Executive Officer [CEO]) to decide if there is money for
acquisition of the medicine.“It will have to go to the CEO’s office; the committee will
write a letter that states there is clinical indication for
the medicine”. [Ob Th PTC]
“It will have to go to the CEO’s office; the committee will
write a letter stating the fact that there is a clinical
indication for the medicine”. [Ob Th PTC]Subtheme 5d: Development of Clinical Guidelines for the
Accepted Medicine
The observations of PTC meetings showed that some of the
PTCs dealt with treatment guidelines in their meetings following
a decision to accept the new medicine onto the hospital
formulary. Clinicians were requested to develop guidelines for
nonformulary medicines that could subsequently be approved by
the committee, the aim being to control the prescribing of these
medicines once on the formulary. In all instances where
guideline development was required, the PTC did not outline
the detail required in the guidelines. However, typically
guidelines were needed before the introduction of a new
medicine as illustrated by the discussion regarding the use of
Precedex® (dexmedetomidine hydrochloride).“The committee will have to develop guidelines on how
to control the use of Precedex®, and outline the patients
who will be eligible for the agent”. [Ob Rh PTC]Theme 6: Decline of an Application
Various reasons were identified for PTCs declining requests.
Subtheme 6a: Requested Medicine Not Registered for the
Indication
Some requests were declined because the medicines requested
were not registered for the specific indication. This was despite
the relative low cost compared to a medicine that was already
being used for the particular indication. The following decision
was taken by the tertiary hospital PTC, illustrating a case where
the request was not accepted:“The challenge is when the motivation is for a medicine
that is not registered for a disease when there is alreadyAugust 2020 | Volume 11 | Article 1267
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Frontia registered product. The concern is if the PTC approves
the motivation and the medicine is used and something
happens to the patient then, who takes responsibility for
that. Clinical data should be provided along with the
motivation”. [Ob Th PTC]Subtheme 6b: Insufficient Evidence From Data Presented
Some requests were rejected by a designated reviewer in the PTC
based on a review of clinical trial data when it was felt that there
was no demonstrated benefit for the indication/ patient
population that the medicine was being considered for. The
reviewer’s explanation during a tertiary level hospital PTC
meeting illustrates the decision taken.“There are reasons why it is not used in these patients,
because there are severe side effects which include 33%
incidence of bone pain. There are quite a few papers on
pneumonia, whatever type CAP, and multilobar. None
of the papers unequivocally says that there is reduced
mortality in these patients. In all these publications
there is no conclusion to say that in severe pneumonia
there will be reduced mortality”. [Ob Th PTC]Theme 7: Removal of Medicines From Formulary List
Subtheme 7a: Decreased Prescribing
The review of the list of medicines during the PTC meetings also
involved removal of medicines, which in some instances was based
on low usage. Such decisions were mostly undertaken at district
hospital PTCs, with the presentations to PTCs mainly undertaken
by the pharmacist. The following examples illustrate this approach:“Clomipramine tablets - the pharmacy suggested the
decoding of clomipramine tablets due to the reduced
usage.” [Ob Dh PTC]Subtheme 7b: EML Changes
Observations of provincial PTCs revealed that they are involved
in an extensive review of all levels of the EML, which resulted in the
removal of a number of medicines from the formulary provincial list.“In total there are now 366 items on the list. 71 items
were removed, 46 items were added. Cimetidine was
discussed an example of an item that had been removed
because it is more costly than ranitidine and it has
many interactions”. [Ob P PTC]In the case of glipizide, the primary care PTC recommended
removal of glipizide from the Gauteng formulary:“The medicine (glipizide) is not included in the EML
and usage in the province is minimal”. [Ob P PTC]Subtheme 7c: Medicine Shortages
The unavailability of medicines due to manufacturing challenges
such as the unavailability of raw materials was also observed asers in Pharmacology | www.frontiersin.org 8one of the reasons for removal of medicines from the formulary,
as illustrated below.“Nitrofurantoin capsules – ‘there has been a raw
material problem for over 1 year, it should therefore
be removed’.” [Ob Dh PTC]Subtheme 7d: Level of Care
Another factor that was considered when removing medicines
from the formulary list was the level of care. As mentioned,
different levels of PTCs serve healthcare facilities that provide
different services. Consequently, the medicines that should be
stocked at each level of care should be specific to the service
provided, as outlined in the EML. The example below was at the
district level of care, which is only allowed to keep medicines
listed in the primary care EML.“Diclofenac injection was introduced as a result of a
request by family physicians; however, the district was
instructed to remove it from its formulary list as it is not
on the primary EML”. [Ob D PTC]Subtheme 7e: Cost of Medicines
At provincial levels cost as consideration when reviewing the
formulary list was as discussed“The review should be evidence based and cost needs
to be brought into consideration through a cost
effectiveness analysis.” [Ob P PTC]The cost of medicines was also considered when considering
the removal of a medicine from the formulary list.“Hydrocortisone cream will be kept in place of the
ointment due to price considerations; it was decided
to remove the ointment”. [Ob D PTC]DISCUSSION
One of the main functions of the PTC is to ensure RUM through
formulary management. In this study, we explored the process
followed by PTCs in the Gauteng Province in performing this
function. It was noteworthy and encouraging that the majority of
PTCs in this study reviewed their formulary lists on an ongoing
basis in line with American Society of Health-System Pharmacists
(ASHP) guidelines (Tyler et al., 2008). This despite the fact that
they were mainly limited to the EML and to an extent the tertiary
medicines lists in the case of tertiary hospital level PTCs, as at the
time the study was conducted the tertiary list had been newly
introduced. While as expected among District Hospital and PHC
level PTCs, there were no applications for non EML medicines,
there was a level of interrogation of available medicines including
adding new medicines from the EML list. The tertiary level PTCs
were the ones who tried to introduce newer medicines as they had
the advantage of access to tertiary and quaternary medicine lists,August 2020 | Volume 11 | Article 1267
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the high quality evidence of the medicine’s efficacy and
effectiveness was required. Typically, clinicians who requested
the new medicine onto the formulary were often present during
the discussion of their application, which provided an opportunity
to clarify any queries. This contrasts with Spain where applicants
did not take part in the evaluation process for new medicines in
57% of cases (Duran-Garcia et al., 2011). We would certainly
endorse clinician involvement more widely where possible,
especially as this enhances formulary adherence as seen for the
‘Wise List’ in Sweden (Gustafsson et al., 2011; Bjorkhem-Bergman
et al., 2013; Eriksen et al., 2017). In instances where high cost
medicines were being requested principally at the tertiary level
PTCs, more thorough evaluations were undertaken. These
included analysis of the efficacy, effectiveness and cost
considerations. This practice is similar to formulary management
processes carried out in the private sector by medical aid schemes
in South Africa (Pharasi andMiot, 2013). Among Danish hospitals,
criteria used for inclusion of medicines onto formularies were
recommendations from professional societies, evidence from the
literature, results from the national tender and the price of the
medicine (Plet et al., 2013). Similarly, Martin et al. (Martin et al.,
2003) and Jenkings et al. (Jenkings and Barber, 2004) found in the
UK that formulary decisions were based on a cluster of factors
including the clinical benefits and the degree of certainty, with local
knowledge also used in the UK (Martin et al., 2003; Jenkings and
Barber, 2004). This is very different to the situation in some other
sub-Saharan African countries where there is very variable PTC
activities even among tertiary hospitals; however, this is not
universal (Directorate of Pharmacy Services, 2012; Office of
Director of Pharmaceutical Services (ODPS) Ministry of Health
Ghana, 2015; Ashigbie et al., 2016; Mudenda et al., 2016; Fadare
et al., 2018b; Anand Paramadhas et al., 2019).
Similarly, there were concerns with the extent of PTC
activities among hospitals in rural Thailand, exacerbated by
concerns with funding and lack of standard criteria for drug
selection (Umnuaypornlert and Kitikannakorn, 2014). However,
the review process was not uniform across all PTC hospital levels
in our study despite the fact that the local EML has specific
guidelines for the application for new medicines to be added to
the EML and therefore the local formulary list. As seen, the
standard information forms were typically not used among the
different levels of hospital care in our study even though this is a
requirement (Gauteng Province Department of Health, 2013; Meyer
et al., 2017). This is a concern and in contrast to a study undertaken
in Jordan where the majority (77%) of DTCs followed structured
guidelines for formulary applications (Alefan et al., 2019).
The practice of lower level PTCs (district hospital and district
PTCs) of only referring to the EML when reviewing level specific
formularies was in accordance with Gauteng Provincial guidelines
(Gauteng Province Department of Health, 2013), and in line with
the findings of Perumal-Pillay and Suleman (Perumal-Pillay and
Suleman, 2017). This was also influenced by the fact that at these
levels, there is a limitation to the types of medicines that can be
used due to a lack of specialized care. However, there is concern
that PTC members among these hospitals lack expertise in EBM.Frontiers in Pharmacology | www.frontiersin.org 9This is important as physician’s trust in recommended medicines
enhances their adherence to recommended medicines (Gustafsson
et al., 2011; Bjorkhem-Bergman et al., 2013; Eriksen et al., 2017).
The use of EMLs in formulary list reviews also took place in
Thailand; however, there were concerns with defining the role of
PTC members and monitoring outcomes of policies (Sudchada
et al., 2012).
Cost considerations were important among all hospital levels
both in terms of evaluating newmore expensive medicines as well
as alternative cheaper but equally effective medicines. This is in
accordance with the Gauteng Provincial guidelines where
if multiple medicines are equally clinically effective, cost
considerations should be a key criteria (Gauteng Province
Department of Health, 2013). This is in line with other
countries (Mannebach et al., 1999; Eddama and Coast, 2008;
Duran-Garcia et al., 2011; Gustafsson et al., 2011; Bjorkhem-
Bergman et al., 2013), with typically indirect costs only
considered in a minority of situations (Mannebach et al., 1999;
Eddama and Coast, 2008). Cost considerations also resulted in
restrictions on which patients should receive the new medicines
especially in tertiary hospitals, similar to a number of European
countries (Godman et al., 2012; Malmstrom et al., 2013;
Parkinson et al., 2015). A key consideration certainly for
tertiary hospitals was whether the local vetting committee had
verified the costings in the application and made the necessary
funds available (Gauteng Province Department of Health, 2013).
The lack of pharmacoeconomic expertise certainly among tertiary
hospitals should be borne in mind when considering formulary
management in developing countries in the future (Matlala et al.,
2017), as lack of expertise may lead to inappropriate use of
medicines that are not cost effective (Pharasi and Miot, 2013).
Co-opting health economics expertise if needed could be one way
forward. However, this will depend on issues of affordability in
LMICs who struggle to fund, for instance biological medicines for
immune conditions as well as insulins and newer oral anti-diabetic
medicines for patients with diabetes (Williams and Bryan, 2007;
Putrik et al., 2014; Baumgart et al., 2019; Godman et al., 2020a;
Godman et al., 2020b). The current lack of pharmacoeconomic
expertise at the provincial level could potentially be addressed by
the adoption of Health Technology Assessment (HTA) principles
included in the NHI Bill (2018) (Meyer et al., 2017).
It is noteworthy that the use of EML/STGs among public
sector hospitals in South Africa limits the degree to which
clinicians can request medicines which do not appear on these
documents. Having said this, it was encouraging especially in
tertiary hospitals that acceptance of new medicines onto the
formulary typically required the development of guidelines
outlining their appropriate use. Laing et al. (2001) found that
substantial involvement and consultation among end users
enhanced the acceptability and usage of the guideline once
available (Laing et al., 2001). We believe this demonstrates that
PTC activity in South Africa can go further than dichotomous
rulings by defining pertinent patient populations for the new
medicine, similar to current practices in for instance Scotland,
Slovenia, Spain and Sweden (Bjorkhem-Bergman et al., 2013;
Godman et al., 2014a; Godman et al., 2015; Matusewicz et al.,August 2020 | Volume 11 | Article 1267
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sector restrictive, when compared to some developed countries.
However, having clinical involvement and a limited list of
medicines enhances adherence and quality of care through
greater physician knowledge of agreed medicines as seen for
instance in Stockholm, Sweden, with the ‘Wise List’ of medicines
(Gustafsson et al., 2011; Bjorkhem-Bergman et al., 2013).
A concern is that even though some PTCs reviewed existing
formulary lists based on medicine usage and availability, the
process was not structured as most presentations were made
verbally. However, this was similar to the study of Abdelrahim
et al. (Abdelrahim et al., 2012), who reported that additions or
removals of medicines were undertaken verbally in five (62.5%)
hospitals (Abdelrahim et al., 2012). The lack of written
documentation for requests to remove medicines from local
formulary lists, i.e. disinvestment, can lead to confusion in future
reviews as there would not be evidence to support such removals;
consequently, lack of accountability. This has however been
addressed by the National Department of Health in the form of
a policy guideline instrument, published in 2019, which includes
documentation to be completed when such requests are submitted
to the PTC (South African National Department of Health, 2019).
Medicine utilization as a basis for removing, reviewing, or
adding medicines to the formulary list, as observed in this study
is encouraging similar to other countries and situations (Persson
et al., 2013; Wehmeyer et al., 2019). However, there is a need to
increase the number of drug utilization studies within hospitals
to improve future medicine use and EBM skills. PTC activities
could also be improved by hospitals sharing their experiences and
expertise. We have seen such approaches used by health authorities
across Europe when implementing policies to improve the use of
resources without compromising care (Godman et al., 2014a;
Godman et al., 2014b; Moon et al., 2014; Godman et al., 2019).
At the time this study was conducted, the only official
national guiding document addressing the functioning of PTCs
was the National Drug Policy (NDOH, 2015). Various provinces
also had their own individual guidelines on the functions and
structures of PTCs, such as the Gauteng Province (Gauteng.
Gauteng Province Department of Health, 2013). In 2015 the first
National Policy for the Establishment and Functioning of PTCs
in South Africa was published (NDOH, 2015), which was then
followed by the publication of the National Guideline for the
Establishment and Functioning of Pharmaceutical and
Therapeutics Committees in South Africa in 2019, providing
the tools and practice guidance for the implementation of the
policy (South African National Department of Health, 2019).
This national guideline (South African National Department of
Health, 2019) articulates the hierarchy for the formulary
development and provides further guidance on other matters
relating to formulary management nationally. These developments
are important, as they will ensure uniformity in formulary
management across the country.
We are aware of a number of limitations with our study. This
included the fact that the study was undertaken in only one
province out of possible nine in South Africa, which may impact
the generalisability of the observations seen. This lack ofFrontiers in Pharmacology | www.frontiersin.org 10generalisability of these results to the rest of the provinces in the
country is influenced further by the autonomy of the various
Provincial Departments of Health. The medicine selection
decisions may vary from province to province, which may result
in inequitable access to medicines and health care products
(Pharasi and Miot, 2013). Gauteng Province is also the most
populated and the economic hub of South Africa, therefore it has
the highest number of central/specialized public sector hospitals in
the country. In addition, PTC members may have been
intimidated by the presence of an observer. We tried though to
make observations as discreetly as possible so as to not influence
the proceedings. However, in view of our methodology, we do
believe our findings are robust providing direction for the future.CONCLUSIONS
We believe this is the first study conducted in the public
healthcare sector in South Africa that has comprehensively
looked at the processes followed by PTCs in their activities.
PTCs at all levels of care were involved in formulary
management, even though they all adopted different approaches
depending on the level of care provided and the expertise of the
committee. Principally, the review of local formularies for
potential inclusion of new medicines was, as expected, guided
by the current EML/STGs and the tertiary list. The approach for
the potential inclusion of new medicines differed among the levels
of care, with tertiary hospital PTCs, which cater for more
specialized services such as oncology and transplant units, able
to request medicines outside of the current EML/STGs. The
decisions were typically based on EBM at the tertiary level and
typically acquisition cost considerations at secondary and primary
care hospitals. This reflects the greater freedom among tertiary
hospitals to list new medicines not included in the standard EML.
The PTCs in Gauteng might not have had more freedom to
include medicines outside of the EML or the tertiary list, but they
still applied the principles of formulary development, observed in
the private sector and other developed countries.
However, a number of concerns were identified. These
included limited utilization of standard forms for requests for
new medicines to be included in the formularies, limited use of
EBM principles for formulary considerations and currently
limited use of drug utilization studies to monitor the subsequent
use of medicines following decisions as well as any impact on
patient care in routine clinical practice. There was also an
identified need for PTCs to learn from each other. In addition,
there was a lack of health economic considerations in formulary
listing decisions. These considerations could becomemore holistic
with recent HTA proposals; though, this remains to be seen.DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made
available by the corresponding author, without undue reservation.August 2020 | Volume 11 | Article 1267
Matlala et al. Formulary Management Activities in Public HospitalsETHICS STATEMENT
The study received ethical clearance from the Medunsa Research
Ethics Committee, University of Limpopo (Medunsa Campus)
and approval from the Gauteng Provincial Department of Health
Research Committee. The respective PTC chairpersons provided
permission to record proceedings, and where permission for
recording was not provided, notes of proceedings were taken.AUTHOR CONTRIBUTIONS
MM, AG, and JM contributed to the conceptualization and
design of the study, and the interpretation of the findings. MM
collected the data. MM and BG undertook the literature review.Frontiers in Pharmacology | www.frontiersin.org 11All authors contributed to the article and approved the
submitted version.FUNDING
MM received a research and development grant from the
University of Limpopo (Medunsa Campus).ACKNOWLEDGMENTS
The authors would like to thank the Gauteng Department of
Health for permission to conduct the study and the various PTCs
for providing permission to collect data during their meetings.REFERENCES
Abdelrahim, S. B., Shaddad, S. A., and Kheder, S. (2012). ssessment of Structure,
Implementation and Activities, Hospital Formulary System in Khartoum State
Hospitals. J. Pharm. Biomed. Sci. 22 (23), 1–6.
Alefan, Q., Alshareef, S., and Al-Shatnawi, S. (2019). Drug and therapeutics
committees in Jordanian hospitals: a nation-wide survey of organization,
activities, and drug selection procedures. Pharm. Pract. 17 (4), 1590. doi:
10.18549/PharmPract.2019.4.1590
Anand Paramadhas, B. D., Tiroyakgosi, C., Mpinda-Joseph, P., Morokotso, M.,
Matome, M., Sinkala, F., et al. (2019). Point prevalence study of antimicrobial
use among hospitals across Botswana; findings and implications. Expert Rev.
Anti-infective Ther. 17 (7), 535–546. doi: 10.1080/14787210.2019.1629288
Ashigbie, P. G., Azameti, D., and Wirtz, V. J. (2016). Challenges of medicines
management in the public and private sector under Ghana’s National Health
Insurance Scheme – A qualitative study. J. Pharm. Policy Pract. 9, 6. doi:
10.1186/s40545-016-0055-9
Attaei, M. W., Khatib, R., McKee, M., Lear, S., Dagenais, G., Igumbor, E. U., et al.
(2017). Availability and affordability of blood pressure-lowering medicines and
the effect on blood pressure control in high-income, middle-income, and low-
income countries: an analysis of the PURE study data. Lancet Public Health 2
(9), e411–e4e9. doi: 10.1016/S2468-2667(17)30141-X
Baumgart, D. C., Misery, L., Naeyaert, S., and Taylor, P. C. (2019). Biological
Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce
Access Inequities? Front. Pharmacol. 10, 279. doi: 10.3389/fphar.2019.00279
Bjorkhem-Bergman, L., Andersen-Karlsson, E., Laing, R., Diogene, E., Melien, O.,
Jirlow, M., et al. (2013). Interface management of pharmacotherapy. Joint
hospital and primary care drug recommendations. Eur. J. Clin. Pharmacol. 69
Suppl 1, 73–78. doi: 10.1007/s00228-013-1497-5
Braun, V., and Clarke, V. (2006). Using thematic analysis in psychology.Qual. Res.
Psychol. 3 (2), 77–101. doi: 10.1191/1478088706qp063oa
Cameron, A., Ewen, M., Ross-Degnan, D., Ball, D., and Laing, R. (2009). Medicine
prices, availability, and affordability in 36 developing and middle-income
countries: a secondary analysis. Lancet 373 (9659), 240–249. doi: 10.1016/
S0140-6736(08)61762-6
Chiatti, C., Bustacchini, S., Furneri, G., Mantovani, L., Cristiani, M., Misuraca, C.,
et al. (2012). The economic burden of inappropriate drug prescribing, lack of
adherence and compliance, adverse drug events in older people: a systematic
review. Drug Saf. 35 Suppl 1, 73–87. doi: 10.1007/BF03319105
Chigome, A. K., Matlala, M., Godman, B., and Meyer, J. C. (2019). Availability and
Use of Therapeutic Interchange Policies in Managing Antimicrobial Shortages
among South African Public Sector Hospitals; Findings and Implications.
Antibiot. (Basel Switzerland) 9 (1), 4. doi: 10.3390/antibiotics9010004
Civaner, M. (2012). Sale strategies of pharmaceutical companies in a
“pharmerging” country: the problems will not improve if the gaps remain.
Health Policy 106 (3), 225–232. doi: 10.1016/j.healthpol.2012.05.006Davies, E. C., Green, C. F., Taylor, S., Williamson, P. R., Mottram, D. R., and
Pirmohamed, M. (2009). Adverse Drug Reactions in Hospital In-Patients: A
Prospective Analysis of 3695 Patient-Episodes. PloS One 4 (2), e4439. doi:
10.1371/journal.pone.0004439
Directorate of Pharmacy Services (2012). Ministry of Health and Child Welfare,
Zimbabwe. Hospital Medicines & Therapeutic Committees - A Practical Guide
to Their Establishment.
Duran-Garcia, E., Santos-Ramos, B., Puigventos-Latorre, F., and Ortega, A. (2011).
Literature review on the structure and operation of Pharmacy and Therapeutics
Committees. Int. J. Clin. Pharm. 33 (3), 475–483. doi: 10.1007/s11096-011-9501-6
Eddama, O., and Coast, J. (2008). A systematic review of the use of economic
evaluation in local decision-making. Health Policy 86 (2-3), 129–141. doi:
10.1016/j.healthpol.2007.11.010
Eriksen, J., Gustafsson, L. L., Ateva, K., Bastholm-Rahmner, P., Ovesjo, M. L.,
Jirlow, M., et al. (2017). High adherence to the ‘Wise List’ treatment
recommendations in Stockholm: a 15-year retrospective review of a
multifaceted approach promoting rational use of medicines. BMJ Open 7 (4),
e014345. doi: 10.1136/bmjopen-2016-014345
Eriksen, J., Ovesjo, M. L., Vallin, M., Juhasz-Haverinen, M., Andersen-Karlsson,
E., Ateva, K., et al. (2018). Primary care physicians report high trust in and
usefulness of the Stockholm drug and therapeutic committee’s list of
recommended essential medicines (the ‘Wise List’). Eur. J. Clin. Pharmacol.
74 (1), 131–138. doi: 10.1007/s00228-017-2354-8
Eriksson, I., Wettermark, B., Persson, M., Edstrom, M., Godman, B., Lindhe, A.,
et al. (2017). The Early Awareness and Alert System in Sweden: History and
Current Status. Front. Pharmacol. 8, 674. doi: 10.3389/fphar.2017.00674
Fadare, J. O., Oshikoya, K. A., Ogunleye, O. O., Desalu, O. O., Ferrario, A., Enwere,
O. O., et al. (2018a). Drug promotional activities in Nigeria: impact on the
prescribing patterns and practices of medical practitioners and the implications.
Hosp. Pract. (1995) 46 (2), 77–87. doi: 10.1080/21548331.2018.1437319
Fadare, J. O., Ogunleye, O., Obiako, R., Orubu, S., Enwere, O., Ajemigbitse, A. A.,
et al. (2018b). Drug and therapeutics committees in Nigeria: evaluation of
scope and functionality. Expert Rev. Clin. Pharmacol. 11 (12), 1255–1262. doi:
10.1080/17512433.2018.1549488
Fadlallah, R., Alkhaled, L., Brax, H., Nasser, M., Rajabbik, M. H., Nass, H., et al.
(2018). Extent of physician-pharmaceutical industry interactions in low- and
middle-income countries: a systematic review. Eur. J. Public Health 28 (2),
224–230. doi: 10.1093/eurpub/ckx204
Formica, D., Sultana, J., Cutroneo, P. M., Lucchesi, S., Angelica, R., Crisafulli, S.,
et al. (2018). The economic burden of preventable adverse drug reactions: a
systematic review of observational studies. Expert Opin. Drug Saf. 17 (7), 681–
695. doi: 10.1080/14740338.2018.1491547
Gauteng Province Department of Health (2013). Guidelines for Implementation of
Pharmaceutical and Therapeutics Committee in Gauteng Province, 1st edition.
Godman, B., Paterson, K., Malmstrom, R. E., Selke, G., Fagot, J. P., and Mrak, J.
(2012). Improving the managed entry of new medicines: sharing experiencesAugust 2020 | Volume 11 | Article 1267
Matlala et al. Formulary Management Activities in Public Hospitalsacross Europe. Expert Rev. Pharmacoeconom. Outcomes Res. 12 (4), 439–441.
doi: 10.1586/erp.12.44
Godman, B., Malmstrom, R. E., Diogene, E., Jayathissa, S., McTaggart, S., Cars, T.,
et al. (2014a). Dabigatran - a continuing exemplar case history demonstrating
the need for comprehensive models to optimize the utilization of new drugs.
Front. Pharmacol. 5, 109. doi: 10.3389/fphar.2014.00109
Godman, B., Wettermark, B., van Woerkom, M., Fraeyman, J., Alvarez-
Madrazo, S., Berg, C., et al. (2014b). Multiple policies to enhance prescribing
efficiency for established medicines in Europe with a particular focus on
demand-side measures: findings and future implications. Front. Pharmacol.
5, 106. doi: 10.3389/fphar.2014.00106
Godman, B., Malmstrom, R. E., Diogene, E., Gray, A., Jayathissa, S., Timoney, A.,
et al. (2015). Are new models needed to optimize the utilization of new
medicines to sustain healthcare systems? Expert Rev. Clin. Pharmacol. 8 (1),
77–94.
Godman, B., Hill, A., Simoens, S., Kurdi, A., Gulbinovič, J., Martin, A. P., et al.
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